(Press-News.org) HRT via skin is best treatment for low bone density in women whose periods have stopped due to anorexia or exercise, says study
Hormone replacement therapy applied via the skin is the best way of protecting bone density in women whose periods have stopped due to anorexia or intense exercise, according to new research from Imperial College London and Imperial College Healthcare NHS Trust.
The study, a meta-analysis of all previous clinical trials, identifies the most effective way to treat women with Functional Hypothalamic Amenorrhoea (FHA), where periods stop because of anorexia nervosa or intense exercise. FHA is a common reproductive disorder, accounting for almost a third of cases of menstrual periods stopping. When periods cease, the resulting lack of natural oestrogen can lead to negative physical changes, particularly regarding bone mineral density.
Approximately half of affected women with FHA suffer from low bone mineral density, compared to only 1% of healthy women, and their risk of bone fractures is up to seven times higher than in the general population.
When women are diagnosed with FHA, doctors will first aim to restore menstrual periods through lifestyle changes, including psychological and dietary interventions, but these are frequently unsuccessful. International clinical guidelines then recommend giving hormone replacement therapy (HRT) containing oestrogen, but the evidence for which form is best has until now been unclear.
The team reviewed all previous randomised clinical trials involving a total of 692 individuals—the largest dataset of its kind—and examined the various therapies available, focusing on their impact on bone mineral density at different sites in the body. As well as looking at different formulations of HRT (oral and transdermal) they investigated teriparatide, a prescription bone-building agent that can be used to treat severe osteoporosis.
They found that:
• Transdermal HRT and teriparatide demonstrated clinically significant benefits on bone mineral density, with reported increases in density typically ranging between 2-13% over 1-2 years depending on patient characteristics, treatment choice and body site
• No significant benefit was observed for oral HRT or the combined oral contraceptive pill.
The study has immediate implications for frontline clinical care, since a recent UK audit found that around a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill to address bone loss. This study suggests such treatment is suboptimal and should be replaced by more effective alternatives like transdermal HRT.
"This study provides much-needed evidence to improve practice and underpin future bone guidelines for this common condition," the researchers noted, emphasizing that the results could drive immediate improvements in how a wide range of specialists—from endocrinologists, GPs, rheumatologists, gynaecologists to psychiatrists—treat the disorder. The researchers added that patients considering their treatment plan should speak to their GP or bone health specialist in the first instance and before making any decisions.
Dr Agathoklis Efthymiadis, Clinical Research Fellow at Imperial College London, said: “Our study provides robust data to improve the management of this condition and inform practice guidelines. Given the present fragmented management of women with amenorrhoea, we believe this will be of interest not just to GPs but to a wide range of specialists, from gynaecologists, rheumatologists and endocrinologists. Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.”
Reflecting a modern approach to clinical research, the researchers shared the findings with women personally affected by FHA, from the Imperial Endocrine Bone Unit at St Mary’s Hospital (part of Imperial College Healthcare NHS Trust), and their insights were also included in the paper.
Professor Alexander Comninos, Professor of Practice at Imperial College London and Consultant Endocrinologist at Imperial College Healthcare NHS Trust where he heads the Endocrine Bone Unit, is the senior author of the study. He said: “Bone density is lost very rapidly in FHA and so addressing bone health early is of paramount importance to reduce the lifelong risk of fractures. Our study provides much-needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is restoration of their normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions - but that is not always possible unfortunately. The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional more effective treatments.”
‘While teriparatide showed benefits at the spine only, we established that giving oestrogen through the skin, or transdermally, improved both bone density in the spine and at the neck of the femur.”
The researchers say there are good scientific reasons why giving the oestrogen transdermally is better than orally and that it was reassuring to see this reflected in the overall results. For example, they say, oral oestrogens can reduce certain bone-forming hormones, whereas transdermal oestrogens do not. Oral oestrogens may typically result in lower ‘active’ oestrogens compared to transdermal oestrogen.
Professor Comninos added: “We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines. This is important as millions of women with FHA may not at present be receiving the best treatments for their bone health.”.
Further large studies are needed in this area directly comparing different forms of oestrogen and progesterone, and in women with different causes of FHA, for example due to purely intense exercise or anorexia nervosa.
The researchers were supported by grants from the Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR), with wider support from the NIHR Imperial Biomedical Research Centre (BRC).
--------------------------------------------------------------------------------
Pharmacological Interventions to Improve Bone Density in Functional Hypothalamic Amenorrhea: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials Open Access. Agathoklis Efthymiadis , Konstantinos Tsikopoulos , Edouard G Mills , Andrew Milne , Waljit S Dhillo , Ali Abbara , Alexander N Comninos (corresponding author).
The Journal of Clinical Endocrinology & Metabolism, February 2026 https://doi.org/10.1210/clinem/dgag005
For more information, please contact:
Sam Rey
Media Officer (Medicine)
Imperial College London
Tel: +44 +44 (0) 020 7594 1507
E-mail: s.rey@imperial.ac.uk / Medicine.media@imperial.ac.uk
Out of hours duty media officer: +44(0) 7803 886 248
This press release uses a labelling system developed by the Academy of Medical Sciences to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf
About Imperial College London
We are Imperial – a world-leading university for science, technology, engineering, medicine and business (STEMB), where scientific imagination leads to world-changing impact.
As a global top ten university in London, we use science to try to understand more of the universe and improve the lives of more people in it. Across our nine campuses and throughout our Imperial Global network, our 22,000 students, 8,000 staff, and partners work together on scientific discovery, innovation and entrepreneurship. Their work navigates some of the world’s toughest challenges in global health, climate change, AI, business leadership and more.
Founded in 1907, Imperial’s future builds on a distinguished past, having pioneered penicillin, holography and fibre optics. Today, Imperial combines exceptional teaching, world-class facilities and a habit of interdisciplinary practice to unlock scientific imagination.
https://www.imperial.ac.uk/
END
HRT via skin is best treatment for low bone density in women whose periods have stopped due to anorexia or exercise, says study
2026-02-06
ELSE PRESS RELEASES FROM THIS DATE:
Insilico Medicine showcases at WHX 2026: Connecting the Middle East with global partners to accelerate translational research
2026-02-06
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced its participation in the World Health Expo 2026 (WHX 2026), held from February 9–12 at the Dubai Exhibition Centre, UAE. As one of the premier global healthcare exhibitions, WHX 2026 serves as a high-impact platform for international healthcare enterprises, research institutions, and investors to explore digital health, biomedical innovation, and life sciences in the Middle East and beyond.
Insilico Medicine, in partnership with the Emirates Drug Establishment (EDE), will present its latest breakthroughs in AI-driven drug discovery at a joint ...
From rice fields to fresh air: Transforming agricultural waste into a shield against indoor pollution
2026-02-06
Formaldehyde is a common but unwelcome guest in many modern homes, leaking silently from furniture, flooring, and household products. While this colorless gas is a known respiratory irritant, cleaning it out of the air usually requires expensive or energy-heavy technology. Now, a research team from Vietnam National University has found a clever way to turn agricultural waste into a high-tech filter that breathes new life into indoor spaces.
In a study published in Carbon Research, the team describes how they successfully ...
University of Houston study offers potential new targets to identify, remediate dyslexia
2026-02-06
A University of Houston psychology professor is challenging the notion that dyslexia, or specific reading disorder, stems from a single faulty gene in the brain, suggesting instead that it is caused by an overall brain network vulnerability. The insight reshapes understanding of one of the world’s most common learning disorders, which affects up to 20% of the world’s population—nearly 780 million people who face lifelong challenges with reading.
Using computers and large biology databases, Elena Grigorenko, Hugh Roy and Lillie Cranz Cullen ...
Scientists uncover hidden role of microalgae in spreading antibiotic resistance in waterways
2026-02-06
Antibiotic resistance is widely recognized as one of the greatest global public health threats, but scientists are now uncovering an unexpected contributor to the problem living quietly in rivers, lakes, and coastal waters. A new review highlights how microalgae, microscopic photosynthetic organisms that support aquatic food webs, may also help concentrate and spread antibiotic resistance genes in natural water environments.
The study, published in the journal Biocontaminant, synthesizes emerging research showing that microalgae ...
Turning orange waste into powerful water-cleaning material
2026-02-06
Researchers have developed an environmentally friendly way to transform discarded orange peels into a highly efficient material that can remove toxic dyes from wastewater, offering a sustainable solution to two growing global challenges: agricultural waste management and water pollution.
Industrial dye pollution is a major environmental problem worldwide. Each year, more than 700,000 tons of synthetic dyes are produced, and a significant portion enters waterways due to incomplete treatment. Even at low concentrations, dyes can discolor water, block sunlight essential for aquatic life, and produce harmful compounds that pose risks to human and ecosystem ...
Papadelis to lead new pediatric brain research center
2026-02-06
Christos Papadelis, a pioneering researcher at The University of Texas at Arlington and leader in the Jane and John Justin Institute for Mind Health at Cook Children’s Health Care System, will serve as the founding director of the UTA Pediatric Brain Health and Neurosciences Center.
The center links clinical and academic communities and bridges the gap between scientific discovery and patient care. Since 2015, UTA has earned the prestigious R1 designation from the Carnegie Classifications of ...
Power of tiny molecular 'flycatcher' surprises through disorder
2026-02-06
For decades, scientists assumed that order drives efficiency. Yet in the bustling machinery of mitochondria — the organelles that crank out adenosine triphosphate (ATP), the universal “energy currency” of cells — one of the most enigmatic components is a protein that appears anything but orderly.
ATP powers nearly every biological task, from muscle contraction to neural signaling, by breaking high-energy phosphate bonds and being continually recharged through metabolism. This life-sustaining energy cycle depends on highly coordinated flows of electrons within respiratory supercomplexes. ...
Before crisis strikes — smartwatch tracks triggers for opioid misuse
2026-02-06
Opioid overdoses continue to take a devastating toll across the United States. According to the U.S. Centers for Disease Control and Prevention (CDC), in 2023, the nation recorded roughly 105,000 drug overdose deaths overall, with nearly 80,000 deaths involving opioids. Worldwide, opioids are also responsible for the majority of drug-related deaths. A University of California San Diego study is working on a potentially life-saving measure that may be as simple as strapping on a smartwatch.
Researchers have ...
Statins do not cause the majority of side effects listed in package leaflets
2026-02-06
Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL (“bad”) cholesterol levels and have been repeatedly proven to reduce the risk of cardiovascular disease. However, there have been concerns about possible side effects.
The researchers gathered data from 23 large-scale randomised studies from the Cholesterol Treatment Trialists’ Collaboration: 123,940 participants in 19 large-scale clinical trials comparing the effects of statin therapies against a placebo (or dummy tablet), and 30,724 participants in four trials comparing more intensive versus less intensive ...
UC Riverside doctoral student awarded prestigious DOE fellowship
2026-02-05
RIVERSIDE, Calif. -- Ryan Milton, a fourth-year doctoral student in nuclear physics at UC Riverside, has been awarded a U.S. Department of Energy’s Office of Science Graduate Student Research (SCGSR) Fellowship. The fellowship, which provides a $3,600 monthly stipend for one year, will support his research at the SLAC National Accelerator Laboratory, part of Stanford University.
“My research focuses on developing and deploying AI tools to understand the behavior of protons and neutrons in nuclei,” Milton said. “Each proton and neutron is made of quarks, but we still don’t fully understand ...